Drug Profile
Research programme: adult stem cell-based therapies - liver regeneration - Lisata Therapeutics/University of California
Latest Information Update: 19 Sep 2022
Price :
$50
*
At a glance
- Originator NeoStem
- Developer University of California, Davis
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Liver-disorders in USA (Parenteral)
- 15 May 2012 Early research in Liver disorders in USA (Parenteral)